SkinBioTherapeutics plc
SkinBioTherapeutics to Present at Investor Evening
Manchester, UK - 19 June 2017 - SkinBioTherapeutics plc (AIM: SBTX, the "Company"), a life science company focused on skin health, is pleased to announce that Dr Catherine O'Neill (CEO) will be presenting at an investor evening held in London, EC4 hosted by Turner Pope Investments (TPI) Ltd.
The event will be held on Thursday 29th June and will commence at 5pm.
To register your interest, please email [email protected] or call 0203 621 4121.
Ends
For more information, please contact:
SkinBioTherapeutics plc Dr. Catherine O'Neill, CEO Douglas Quinn, CFO |
Tel: +44 (0) 161 468 2760 |
Turner Pope Investments Ben Turner / James Pope |
Tel: +44 (0) 20 3621 4120 |
Instinctif Partners Melanie Toyne-Sewell / Alex Shaw / Deborah Bell |
Tel: +44 (0) 20 7457 2020 [email protected] |
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising £4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.
